摘要:目的 探讨在进行胃癌筛查过程中，分析胃蛋白酶原Ⅰ（PGⅠ）以及胃蛋白酶原Ⅱ（PGⅡ）的诊断应用价值。方法选择2012年5月至2014年5月胃癌患者15例，萎缩性胃炎患者20例，胃溃疡患者23例，浅表性胃炎患者25例以及健康体检人员80例。利用胶乳增强免疫透射比浊法分别测定实验人员的PGⅠ与PGⅡ含量，最终得出PGR。结果 PGⅠ：胃癌37.13±18.59ng/mL；萎缩性胃炎39.27±16.29ng/mL；胃溃疡180.42±61.27ng/mL；浅表性胃炎128.12±14.65ng/mL；健康体检人员120.19±16.96ng/mL；同健康对照组进行比较，胃癌组以及萎缩性胃炎组患者低于其明显（P<0.05）；PGⅡ：胃癌20.67±9.59ng/mL；萎缩性胃炎患者16.35±16.89ng/mL；胃溃疡患者22.95±13.46ng/mL；浅表性胃炎8.05±4.04ng/mL；健康体检人员11.85±9.65ng/mL；每组之间差异无统计学意义（P>0.05）。在PGⅠ与PGⅡ阳性检出率方面，胃癌组与萎缩性胃炎组明显高于其他组（P<0.05）。结论 对体检人员的PGⅠ与PGⅡ进行测定，对于胃癌疾病以及萎缩性胃炎疾病的筛查以及诊断能够提供充分依据，表现出显著价值。

Abstract: Objective To explore the diagnostic value of pepsinogen Ⅰ (PG Ⅰ) and pepsin Ⅱ (PG Ⅱ) in the screening for gastric cancer. Methods 15 patients with gastric cancer, 20 patients with atrophic gastritis, 23 cases of gastric ulcer patients, 25 cases of superficial gastritis patients and 80 healthy physical examination personnel were selected in this study. The PG Ⅰ and PG Ⅱ content were detected by using latex enhanced immune transmission turbidimetry. Results The PG Ⅰ content in gastric cancer patients, patients with atrophic gastritis, gastric ulcer patients, superficial gastritis patients and physical examination personnel were 37.13 ±18.59 ng/ml, 39.27 ± 16.29 ng/mL, 180.42 ± 61.27 ng/mL, 128.12 ±14.65 ng/mL and 120.19 ± 16.96 ng/mL respectively. The PG I in patients with gastric cancer and atrophic gastritis group were significantly lower than that of normal controls (P < 0.05). The PG Ⅱcontent in gastric cancer patients, patients with atrophic gastritis, gastric ulcer patients, superficial gastritis patients and physical examination personnel were 20.67 ±9.59 ng/mL, 16.35 ±16.89 ng/mL, 22.95 ±13.46 ng/mL, 8.05 ± 4.04 ng/ml, and 11.85 ±9.65 ng/mL respectively. There was no significant difference between each groups (P>0.05). The positive rate of PG Ⅰ and PG Ⅱ in patients with gastric cancer and atrophic gastritis group were significantly higher than other groups (P < 0.05). Conclusion The detection of PG Ⅰ and PG Ⅱcould provide significant value in the gastric cancer and atrophic gastritis disease screening and diagnosis.